Abstract
The pharmacokinetics of quinine were investigated in a) six healthy male Thai subjects, and b) nine male Thai patients with a moderate degree of chronic liver disease, after a single oral dose of 600 mg quinine sulphate. tmax and t1/2.2 were significantly prolonged in patients (median [range] tmax 2 [1‐5] vs 1.6 [0.8‐2] h; t1/2,z 23.4 [17.4‐41.7] vs 9.7 [7.8‐17.2] h), and Vz/F was significantly larger (median [range] 4.21 [2.33‐15.87] vs 2.78 [1.49‐3.38] 1 kg‐1). Median (range) concentration of the plasma unbound Qn fraction collected from the patients at 4 h after drug administration was 17 (8.4‐17.8)% of total drug concentration. Copyright © 1995, Wiley Blackwell. All rights reserved
Cite
CITATION STYLE
Auprayoon, P., Sukontason, K., Na‐Bangchang, K., Banmairuroi, V., Molunto, P., & Karbwang, J. (1995). Pharmacokinetics of quinine in chronic liver disease. British Journal of Clinical Pharmacology, 40(5), 494–497. https://doi.org/10.1111/j.1365-2125.1995.tb05795.x
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.